ProtoKinetix, Inc. Overview
Pro stress-test →ProtoKinetix is a research and development stage biotechnology company focused on scientific medical research of anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). Its AFGPs are used in various commercial applications comprising targeted health care solutions, while AAGPs are used for applications in ophthalmology, dermatology, transplants, and biomanufacturing.
Strategic Profile
Pro stress-test →The company's patented anti-aging glycopeptide (AAGP) is based on a molecule found in nature and developed by a world-class research team, with the capability to help more cells survive longer. ProtoKinetix has partnered with IQVIA to accelerate clinical development and regulatory progress of PKX-001 in ocular conditions, specifically dry eye disease and age-related macular degeneration.
Competitive Landscape
Pro stress-test →ProtoKinetix operates in a highly specialized biotech space with no direct competitors for its proprietary AAGP molecule. However, it competes indirectly with established biopharmaceutical companies developing cell preservation technologies, dry eye disease treatments, and transplant-related therapies. The company's ultra-early-stage clinical development positions it pre-competitive relative to marketed ophthalmology and regenerative medicine solutions.
Industry Context
ProtoKinetix, Inc. operates in Biotech cell preservation and regenerative medicine.
Key facts
Founded: 1999 · Headquarters: Dalton, OH · Employees: Unknown · Revenue: $0 · Market cap: $1.7M